HDAC6 and neuroblastoma: Thiol-based HDAC6 inhibitors, such as compound St.24, underscored notable potency and selectivity with potentially improved pharmacokinetics, while sulfur-containing derivatives like compound St.28 showed HDAC8 selectivity and in vivo antitumor efficacy in neuroblastoma models.